SK Biopharm Signs Radioisotope Supply Agreement with Germany's Eckert & Ziegler

Securing Raw Materials in Europe
Diversifying the Actinium-225 Supply Chain

SK Biopharm has proactively established a supply chain for actinium-225 in Europe, creating a stable environment for the development of radiopharmaceuticals (RPTs).

Eckert & Ziegler. SK Biopharm

On December 2, SK Biopharm announced that it had signed a supply agreement for actinium-225 (225Ac) with Eckert & Ziegler, a German company specializing in radioactive isotopes (RIs) with GMP (Good Manufacturing Practice) certification for pharmaceuticals.

Actinium-225 is a core material for next-generation anticancer RPTs, as it possesses strong cancer cell-killing power while causing relatively few side effects. However, global production is extremely limited, making stable sourcing of this raw material a critical factor for successful RPT development.

This agreement is significant in that it strengthens the supply stability of the rare raw material actinium-225 by securing an independent supply line within Europe, moving beyond the existing North America-centered supply structure. Previously, in August last year and February this year, SK Biopharm diversified its actinium-225 sourcing channels through collaborations with two global RI suppliers. With this new agreement, the company has further reinforced its network in Europe-a major market for RPTs-laying the foundation for global business expansion.

SK Biopharm plans to accelerate research and development in the RPT field based on a stable supply of actinium-225. The company is expanding its RPT pipeline and strengthening its next-generation anticancer drug development capabilities by pursuing both internal research projects and inorganic growth strategies. Last year, SK Biopharm introduced 'SKL35501' from Full-Life Technologies as its first RPT candidate and is currently preparing to submit an Investigational New Drug (IND) application for Phase 1 clinical trials. More recently, the company also acquired a second candidate, 'WT-7695,' from the Wisconsin Alumni Research Foundation (WARF).

Harald Hasselmann, CEO of Eckert & Ziegler, said, "We are very pleased to supply GMP-certified actinium-225 for SK Biopharm's preclinical and clinical programs. Actinium-225 is one of the essential core RIs for next-generation RPT development, and we are proud to contribute to the advancement of anticancer therapeutics."

Lee Donghoon, CEO of SK Biopharm, stated, "Stabilizing the supply of actinium-225, a key raw material for RPTs, is a prerequisite for successful new drug development. Signing this agreement with Eckert & Ziegler, a company with extensive experience and reliability in high-quality RI supply, is highly significant. Leveraging our proactively established global partnerships and diversified supply chain, we will actively pursue the global anticancer drug market."

This content was produced with the assistance of AI translation services.